Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Pfizer's Inclacumab?
Inclacumab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease With Vaso-Occlusive...
Inclacumab by Pfizer for Sickle Cell Disease With Vaso-Occlusive Crisis: Likelihood of Approval
Inclacumab is under clinical development by Pfizer and currently in Phase III for Sickle Cell Disease With Vaso-Occlusive Crisis. According...
Risk adjusted net present value: What is the current valuation of Pfizer's Inclacumab?
Inclacumab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease With Vaso-Occlusive...